A Vantage analysis identifies 315 pivotal trials that, like Lexicon’s Scored and Soloist studies, risk never being completed.
Drug makers from across the globe feature in 2019’s list of best performing small biotech stocks, from Galapagos to Daiichi Sankyo to Arrowhead.
The pivotal portion of bardoxolone’s Cardinal study can’t match earlier data, but is still sufficient for filing.
Fresh from buying omaveloxolone and bardoxolone rights back from Abbvie, Reata sees the first part of the puzzle fall into place.
Biontech and ADC Therapeutics are both heading towards substantial flotations, but it is hard to find evidence that bigger does better.
Reata Pharmaceuticals will soon find out if its decision to persevere with omaveloxolone despite an earlier failure has paid off.
Hopes are high as a phase III readout approaches for Reata Pharmaceuticals’ lead project, bardoxolone.